Portrait of the PI3K/AKT pathway in colorectal cancer
SA Danielsen, PW Eide, A Nesbakken, T Guren… - … et Biophysica Acta (BBA …, 2015 - Elsevier
Abstract PI3K/AKT signaling leads to reduced apoptosis, stimulates cell growth and
increases proliferation. Under normal conditions, PI3K/AKT activation is tightly controlled …
increases proliferation. Under normal conditions, PI3K/AKT activation is tightly controlled …
[HTML][HTML] New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?
Anti-epidermal growth factor receptor therapy with the monoclonal antibodies cetuximab and
panitumumab is the main targeted treatment to combine with standard chemotherapy for …
panitumumab is the main targeted treatment to combine with standard chemotherapy for …
[HTML][HTML] A comprehensive review of clinical trials on EGFR inhibitors such as cetuximab and panitumumab as monotherapy and in combination for treatment of …
Metastatic colorectal cancer is the fourth most common cause of death due to cancer after
those of lung, stomach, and liver. Anti epidermal growth factor receptor drugs as a targeting …
those of lung, stomach, and liver. Anti epidermal growth factor receptor drugs as a targeting …
Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: a systematic review and meta-analysis
O Abdel-Rahman, M Fouad - Critical Reviews in Oncology/Hematology, 2015 - Elsevier
Background We performed a systematic review and meta-analysis of the correlation
between cetuximab-induced skin rash and outcomes of solid tumor patients treated with …
between cetuximab-induced skin rash and outcomes of solid tumor patients treated with …
Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy
MKH Maus, DL Hanna, CL Stephens… - The …, 2015 - nature.com
Colorectal cancer (CRC) is a heterogeneous disease with genetic profiles and clinical
outcomes dependent on the anatomic location of the primary tumor. How location has an …
outcomes dependent on the anatomic location of the primary tumor. How location has an …
Cadmium at nanomolar concentrations activates Raf–MEK–ERK1/2 MAPKs signaling via EGFR in human cancer cell lines
Cadmium (Cd) is an environmental contaminant classified as carcinogenic to humans by the
International Agency for Research on Cancer, supported by data from occupational …
International Agency for Research on Cancer, supported by data from occupational …
[HTML][HTML] Cetuximab reconstitutes pro-inflammatory cytokine secretions and tumor-infiltrating capabilities of sMICA-inhibited NK cells in HNSCC tumor spheroids
S Kloess, N Chambron, T Gardlowski, S Weil… - Frontiers in …, 2015 - frontiersin.org
Immunosuppressive factors, such as soluble major histocompatibility complex class I chain-
related peptide A (sMICA) and transforming growth factor beta 1 (TGF-β1), are involved in …
related peptide A (sMICA) and transforming growth factor beta 1 (TGF-β1), are involved in …
Prophylactic effect of oral minocycline in combination with topical steroid and skin care against panitumumab-induced acneiform rash in metastatic colorectal cancer …
M Yamada, H Iihara, H Fujii, M Ishihara… - Anticancer …, 2015 - ar.iiarjournals.org
Background: Although the anti-EGFR monoclonal antibody panitumumab is effective in
treating colorectal cancer, the occurrence of severe skin disorders often discontinues …
treating colorectal cancer, the occurrence of severe skin disorders often discontinues …
[HTML][HTML] Standard chemotherapy with cetuximab for treatment of colorectal cancer
XX Li, L Liang, LY Huang, SJ Cai - World Journal of …, 2015 - ncbi.nlm.nih.gov
AIM: To review and assess the evidence related to cetuximab treatment in metastatic
colorectal cancer (mCRC) with regard to KRAS status. METHODS: PubMed, EMBASE …
colorectal cancer (mCRC) with regard to KRAS status. METHODS: PubMed, EMBASE …
IgG1 anti‐epidermal growth factor receptor antibodies induce CD8‐dependent antitumor activity
J Kubach, M Hubo, C Amendt, C Stroh… - … Journal of Cancer, 2015 - Wiley Online Library
Anti‐EGFR monoclonal antibodies (mAb) like Cetuximab are commonly used for treatment
of EGFR+ solid tumors mainly by exerting their therapeutic effect through inhibition of signal …
of EGFR+ solid tumors mainly by exerting their therapeutic effect through inhibition of signal …